Skip to main content

Drug Interactions between cangrelor and prasugrel

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

prasugrel cangrelor

Applies to: prasugrel and cangrelor

ADJUST DOSING INTERVAL: The antiplatelet effect of clopidogrel or prasugrel may be inhibited when they are administered at the same time as cangrelor. The mechanism is competitive inhibition of P2Y12 platelet receptors by cangrelor, which, unlike clopidogrel or prasugrel, binds reversibly at the receptor site and causes a temporary rather than persistent inhibition of ADP-induced platelet activation and aggregation. According to the product labeling for cangrelor, the expected antiplatelet effect of a 600 mg loading dose of clopidogrel or a 60 mg loading dose of prasugrel was blocked when these agents were administered during a cangrelor infusion. Conversely, pretreatment with clopidogrel or prasugrel does not impair the antiplatelet effect of cangrelor, but may result in additive platelet inhibition.

MANAGEMENT: To maintain platelet inhibition, clopidogrel 600 mg or prasugrel 60 mg should be administered immediately after discontinuation of the cangrelor infusion. Do not administer prior to discontinuation of cangrelor, as clopidogrel and prasugrel will have no antiplatelet effect until the next dose is administered. Alternatively, ticagrelor 180 mg may be administered at any time during cangrelor infusion or immediately after discontinuation.

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S (2008) "The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function." J Thromb Haemost, 6, p. 1153-9
  3. (2015) "Product Information. Kengreal (cangrelor)." The Medicines Company

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Adp receptor antagonists

Therapeutic duplication

The recommended maximum number of medicines in the 'ADP receptor antagonists' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'ADP receptor antagonists' category:

  • cangrelor
  • prasugrel

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer